The field of HIV vaccine and prevention research continues to evolve as new insights are gained through animal studies and clinical trials. The Vaccine Discovery Group (VDG) aims to support this CHAVI-ID by providing insight and guidance to adjust research aims based on new findings during the life of the Center. This VDG will involve leadership from the clinical HIV vaccine field, along with key researchers with biotech, pharmaceutical and academic experience. Specifically, the VDG will provide guidance on vaccine development and administration based on personal insights and experiences in the field, and will provide data on how best to blend new outside knowledge into the research focus and aims of the CHAVI-ID, thereby ensuring the work of the Center remains at the forefront of addressing critical questions in the HIV vaccine research field. This will be accomplished by the following Specific Aims: 1. To share basic, practical knowledge about vaccine development and formulate creative strategies to advance ideas to products. 2. To provide sustained guidance to enable promising HlV-1 vaccine candidates to move forward into clinical evaluation.
This Discovery Group supports the CHAVI-ID by providing direct linkages with the leaders and advisors in the clinical vaccine networks to more efficiently move products into phase 1 testing. This is critical for supporting the immunogen discovery activities of the Center.
|Scheid, Johannes F; Horwitz, Joshua A; Bar-On, Yotam et al. (2016) HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535:556-60|
|Barton, John P; Goonetilleke, Nilu; Butler, Thomas C et al. (2016) Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nat Commun 7:11660|
|Briney, Bryan; Sok, Devin; Jardine, Joseph G et al. (2016) Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell 166:1459-1470.e11|
|Landais, Elise; Huang, Xiayu; Havenar-Daughton, Colin et al. (2016) Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. PLoS Pathog 12:e1005369|
|van Gils, Marit J; van den Kerkhof, Tom L G M; Ozorowski, Gabriel et al. (2016) An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat Microbiol 2:16199|
|Moldt, Brian; Le, Khoa; Carnathan, Diane G et al. (2016) Neutralizing antibody affords comparable protection against vaginal and rectal SHIV challenge in macaques. AIDS :|
|Lu, Ching-Lan; Murakowski, Dariusz K; Bournazos, Stylianos et al. (2016) Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352:1001-4|
|Tam, Hok Hei; Melo, Mariane B; Kang, Myungsun et al. (2016) Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci U S A 113:E6639-E6648|
|Havenar-Daughton, Colin; Carnathan, Diane G; Torrents de la PeÃ±a, Alba et al. (2016) Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. Cell Rep 17:2195-2209|
|Dan, Jennifer M; Lindestam Arlehamn, Cecilia S; Weiskopf, Daniela et al. (2016) A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. J Immunol 197:983-93|
Showing the most recent 10 out of 206 publications